First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study

PURPOSE. The aim of this phase III trial was to compare the efficacy and safety of bevacizumab alone with those of bevacizumab and capecitabine plus oxaliplatin (XELOX) as maintenance treatment following induction chemotherapy with XELOX plus bevacizumab in the first-line treatment of patients with...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Díaz-Rubio, Eduardo, Gómez-España, Auxiliadora, Massutí, Bartomeu, Sastre, Javier, Abad, Albert, Valladares, Manuel, Rivera, Fernando, Safont, Maria J., Martínez de Prado, Purificación, Gallén, Manuel, González, Encarnación, Marcuello, Eugenio, Benavides, Manuel, Fernández-Martos, Carlos, Losa, Ferrán, Escudero, Pilar, Arrivi, Antonio, Cervantes, Andrés, Dueñas, Rosario, López-Ladrón, Amelia, Lacasta, Adelaida, Llanos, Marta, Tabernero, Jose M., Antón, Antonio, Aranda, Enrique
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: AlphaMed Press 2012
Pynciau:
Academia-Pharma Intersect
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3267817/
https://ncbi.nlm.nih.gov/pubmed/22234633
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0249
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg